MRNA

The past six months have been a windfall for Moderna’s shareholders. The company’s stock price has jumped 46.4%, hitting $62.97 per share. This was partly thanks to its solid quarterly results, and the run-up might have investors contemplating their next move. Is there a buying opportunity in Moderna, or does it present a risk to your portfolio? Get the full breakdown from our expert analysts, it’s free. Despite the momentum, we’re sitting this one out for now. Here are three reasons we avoid MRNA, plus one stock we’d rather own. A company’s long-term sales performance can indicate its overall quality. Any business can have short-term success, but a top-tier one grows for years. Moderna’s demand was weak over the last five years as its sales fell at a 4% annual rate. This wasn’t a great result and signals it’s a low quality business. Analyzing the long-term change in earnings per share (EPS) shows whether a company’s incremental sales were profitable — for example, revenue could be inflated through excessive spending on advertising and promotions. Sadly for Moderna, its EPS declined by 46.5% annually over the last five years, more than its revenue. This tells us the company struggled because its fixed cost base made it difficult to adjust to shrinking demand. If you’ve followed StockStory for a while, you know we emphasize free cash flow. Why, you ask? We believe that in the end, cash is king, and you can’t use accounting profits to pay the bills. As you can see below, Moderna’s margin dropped meaningfully over the last five years. It may have ticked higher more recently, but shareholders are likely hoping for its margin to at least revert to its historical level. If the longer-term trend returns, it could signal it is in the middle of an investment cycle. Moderna’s free cash flow margin for the trailing 12 months was negative 72%. Moderna doesn’t pass our quality test. Following the recent surge, the stock trades at $62.97 per share (or a forward price-to-sales ratio of 14×). The market typically values companies like Moderna based on their anticipated profits for the next 12 months, but it expects the business to lose money. We also think the upside isn’t great compared to the potential downside here - there are more exciting stocks to buy. Let us point you toward the Amazon and PayPal of Latin America. ONE MORE THING: Top 6 Stocks for This Week. This mark...

Get insights on thousands of stocks from the global community of over 7 million individual investors at Simply Wall St. US stock futures are pointing higher this morning, with E-mini S&P 500 contracts up about 0.4%, as investors digest a mix of cooling inflation and uneven growth signals abroad. Softer price data in countries like France, where inflation sits at 1.8%, suggests global cost of living pressures are easing, which can take some pressure off central banks to keep lifting interest rates. At the same time, weaker industrial output in places such as Italy and Turkey hints at slower factory activity worldwide. The key question now is whether this mix helps interest rate sensitive sectors like real estate and utilities more than it hurts globally exposed manufacturers and commodity linked stocks. With inflation cooling but global growth looking uneven, many investors are gravitating toward 79 resilient stocks with low risk scores. Cerebras Systems (CBRS) jumped 8.34% after announcing expanded manufacturing and new European AI infrastructure capacity. Meta Platforms (META) rose 5.97% as investors focused on its AI chips, models, and cloud compute plans. SBA Communications (SBAC) gained 4.14%. Is Cerebras Systems still a smart investment or just hype? Read our most popular narrative and get all the answers you need. Moderna (MRNA) fell 10.83% as investors reacted to renewed political focus on vaccine skepticism and policy. Okta (OKTA) declined 6.86%. MongoDB (MDB) dropped 5.73% despite recent analyst price target increases and supportive research coverage. For a broader view of how yesterday's selling pressure fits into overall risk, it can help to scan across sectors and compare balance sheets, cash flows, and volatility metrics in one place using 79 resilient stocks with low risk scores. Look past the noise - uncover the top narrative that explains what truly matters for Okta's long-term success. Big bank earnings are about to dominate the US market narrative, setting the tone for financials and credit trends. Big Bank Earnings: JPMorgan Chase (JPM), Wells Fargo (WFC), Citigroup (C), Goldman Sachs (GS) and Bank of America (BAC) on Tuesday will spotlight lending, trading and fee income trends. Asset Management Focus: BlackRock (BLK) on Wednesday will highlight flows into funds and investor appetite for risk assets. Banking Services Snapshot: PNC Financi...

CAMBRIDGE, MA / ACCESS Newswire / July 9, 2026 / Moderna, Inc. (NASDAQ:MRNA), today announced that it will host a live conference call and webcast at 8:00 a.m. ET on Friday, July 31, 2026 to report its second quarter 2026 financial results, and provide a corporate update. A live webcast of the call will be available under "Events and Presentations" in the Investors section of the Moderna website. Webcast: https://investors.modernatx.com The archived webcast will be available on Moderna's website approximately two hours after the conference call and will be available for one year following the call. About Moderna Moderna is a pioneer and leader in the field of mRNA medicine. Through the advancement of its technology platform, Moderna is reimagining how medicines are made to transform how we treat and prevent diseases. Since its founding, Moderna's mRNA platform has enabled the development of vaccines and therapeutics across infectious diseases, cancer, rare diseases and more. With a global team and a unique culture, driven by the company's values and mindsets, Moderna's mission is to deliver the greatest possible impact to people through mRNA medicines. For more information about Moderna, please visit modernatx.com and connect with us on X, Facebook, Instagram, YouTube and LinkedIn. Investors:Lavina TalukdarSenior Vice President & Head of Investor [email protected] SOURCE: Moderna, Inc. View the original press release on ACCESS Newswire

Moderna (MRNA), TG Therapeutics (TGTX), and Agios Pharmaceuticals (AGIO) will see increased scrutiny

Arbutus Biopharma Corporation (NASDAQ:ABUS) is one of the 10 Most Profitable Small Cap Stocks to Buy. On May 13, 2026, Arbutus Biopharma Corporation (NASDAQ:ABUS) reported Q1 2026 revenue of $179.1 million with estimated license revenue tied to its litigation settlement with Moderna. The company said revenue jumped from $1.8 million a year earlier because of the increase in its share of a noncontingent settlement payment through Genevant Sciences. Arbutus Biopharma Corporation (NASDAQ:ABUS) reported net income of $169.7 million from a $24.5 million loss. The research and development expenses dropped to $4.1 million from $9.0 million with cost reductions and lower trial activity. General and administrative expenses edged higher to $5.9 million due to legal costs, the company added. Separately, the firm said the US Food and Drug Administration granted Fast Track designation to imdusiran. It noted that the program could speed up development and review timelines. The corporation ended the quarter with $95.2 million in cash and investments, making its financial position solid, it said. Arbutus Biopharma Corporation (NASDAQ:ABUS) is a clinical-stage biopharmaceutical firm. It is involved in developing novel therapeutics that target specific viral diseases. While we acknowledge the potential of ABUS as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: 33 Stocks That Should Double in 3 Years and Cathie Wood 2026 Portfolio: 10 Best Stocks to Buy. Disclosure: None. Follow Insider Monkey on Google News.

A month has gone by since the last earnings report for Novavax (NVAX). Shares have added about 10.4% in that time frame, outperforming the S&P 500. Will the recent positive trend continue leading up to its next earnings release, or is Novavax due for a pullback? Well, first let's take a quick look at its most recent earnings report in order to get a better handle on the recent drivers for Novavax, Inc. before we dive into how investors and analysts have reacted as of late. Novavax incurred a loss of 6 cents per share in the first quarter of 2026, narrower than the Zacks Consensus Estimate of a loss of 25 cents. In the year-ago quarter, the company had recorded EPS of $2.93, driven by higher sales. Quarterly revenues totaled $139.5 million, down 79% year over year. This metric beat the Zacks Consensus Estimate of $69.5 million. A key theme this quarter was the shifting composition of revenues as NVAX prioritizes monetizing Matrix-M through partners. Product sales were led by supply activity and direct demand for the company’s COVID-19 vaccine, Nuvaxovid, in a smaller set of markets, while partner-related revenues benefited from licensing activity across multiple counterparties. Novavax recorded $42.2 million in product sales, down 93% year over year. This includes about $10 million from Nuvaxovid, reflecting sales primarily in Germany for the 2025-2026 season and the continued transition of commercial responsibility in Europe to Sanofi. Supply sales were nearly $33 million, up 136% year over year, supported by higher demand for Matrix-M adjuvant from partners as well as COVID-19 supply to Sanofi. Last year, Sanofi acquired exclusive rights to market Nuvaxovid globally, except in certain territories where Novavax maintains existing partnership agreements. Licensing, royalties and other revenues totaled $97.3 million, including $30 million recognized as an upfront payment received from Pfizer in connection with a non-exclusive license agreement for Matrix-M signed earlier this year. The metric increased 116% on a year-over-year basis. Research and development (R&D) expenses totaled $95.5 million, up 7% year over year, driven by increased costs tied to post-marketing commitments and annual strain change activities. This figure does not include the $28 million of R&D reimbursement from Sanofi. Selling, general and administrative (SG&A) expenses declined 40% to $2...

It has been about a month since the last earnings report for Ultragenyx (RARE). Shares have lost about 13.6% in that time frame, underperforming the S&P 500. But investors have to be wondering, will the recent negative trend continue leading up to its next earnings release, or is Ultragenyx due for a breakout? Before we dive into how investors and analysts have reacted as of late, let's take a quick look at its latest earnings report in order to get a better handle on the important catalysts. Ultragenyx reported first-quarter 2026 loss of $1.84 per share, wider than the Zacks Consensus Estimate of a loss of $1.55. The company had incurred a loss of $1.57 per share in the year-ago quarter. Ultragenyx’s total revenues amounted to $136 million in the reported quarter, which declined 2% year over year due to lower product sales. The top line missed the Zacks Consensus Estimate of $161 million. Crysvita’s total revenues were $93 million, down 10% year over year, due to expected seasonality in the U.S. and Canada and ordering patterns in Brazil. Crysvita’s net product revenues in the first quarter of 2026 included $39 million from North America, $46 million from Latin America and Turkey, and $8 million from Europe. Mepsevii product revenues decreased 13% year over year to $7 million in the reported quarter. Dojolvi product revenues were $18 million, up 6%, driven by new patient demand. Evkeeza recorded sales of $18 million in the first quarter, up 64%, driven by increased demand from new country launches and early access. Operating expenses of $305 million in the quarter rose 8% year over year due to increased investments in multiple late-stage pipeline programs and marketing costs for approved drugs. Operating expenses included research and development (R&D) expenses of $187 million (up 13%), selling, general and administrative (SG&A) expenses of $88 million (up 1%) and cost of sales of $30 million (up 3%). Cash, cash equivalents and marketable securities amounted to $534 million as of March 31, 2026, compared with $737 million as of Dec. 31, 2025. Ultragenyx continues to expect total revenues in 2026, excluding potential revenues from new product launches, between $730 million and $760 million, which suggests growth of approximately 8-13% compared to 2025. Crysvita revenues in 2026 are expected to be in the range of $500-$520 million, indicating growing underlyi...

Earnings season is winding down, but we still have a couple of big name companies reporting. This week we have Broadcom (AVGO), Crowdstrike (CRWD), Palo Alto Networks (PANW), Medtronic (MDT) and Ciena Corp (CIEN) all reporting. Before a company reports earnings, implied volatility is usually high because the market is unsure about the outcome of the report. Speculators and hedgers create huge demand for the company’s options which increases the implied volatility, and therefore, the price of options. Jobs Data, Tech Earnings and Other Key Things to Watch this Week Northrop Grumman Just Hiked Its Dividend, But Its Stock Has Tanked - Time to Buy NOC? Dell Stock Could Be Worth 30% More - Based on Strong AI Demand and FCF Our exclusive Barchart Brief newsletter is your FREE midday guide to what's moving stocks, sectors, and investor sentiment - delivered right when you need the info most. Subscribe today! After the earnings announcement, implied volatility usually drops back down to normal levels. Let’s take a look at the expected range for these stocks. To calculate the expected range, look up the option chain and add together the price of the at-the-money put option and the at-the-money call option. Use the first expiry date after the earnings date. While this approach is not as accurate as a detailed calculation, it does serve as a reasonably accurate estimate. Monday HPE – 17.7% CRDO – 18.8% Tuesday PANW – 11.2% Wednesday AVGO – 9.6% CRWD – 10.3% MDT – 5.1% Thursday CIEN – 16.4% Friday Nothing of note Option traders can use these expected moves to structure trades. Bearish traders can look at selling bear call spreads outside the expected range. Bullish traders can sell bull put spreads outside the expected range, or look at naked puts for those with a higher risk tolerance. Neutral traders can look at iron condors. When trading iron condors over earnings, it is best to keep the short strikes outside the expected range. When trading options over earnings, it is best to stick to risk defined strategies and keep position size small. If the stock makes a larger than expected move and the trade suffers a full loss, it should not have more than a 1-3% effect on your portfolio. We can use Barchart’s Stock Screener to find other stocks with high implied volatility. Let’s run the stock screener with the following filters: Total call volume: Greater than 5,000 Market...

This article first appeared on GuruFocus. Cash and Cash Equivalents: $4.3 billion as of March 31, 2026, before the Moderna settlement. Debt: No debt reported. Moderna Settlement: $2.25 billion settlement with $950 million upfront expected in July. R&D Expenses: Increased due to the expansion of program scope. Share Repurchase: Active share repurchase program ongoing. Warning! GuruFocus has detected 7 Warning Signs with ROIV. Is ROIV fairly valued? Test your thesis with our free DCF calculator. Release Date: May 20, 2026 For the complete transcript of the earnings call, please refer to the full earnings call transcript. Roivant Sciences Ltd (NASDAQ:ROIV) reported strong clinical data from its 1,402 study, showing high ACR response rates, with 73% of patients achieving ACR20, over half achieving ACR50, and over a third achieving ACR70. The company received breakthrough therapy designation for PrEP/Sitnib for retinue sarcoidosis, highlighting its potential impact on patient treatment. Roivant Sciences Ltd (NASDAQ:ROIV) announced a $2.25 billion settlement with Moderna, with $950 million expected upfront in July, strengthening its financial position. The company is on track to launch brevacitinib for dermatomyositis by the end of September, pending FDA approval, indicating strong commercial preparation. Roivant Sciences Ltd (NASDAQ:ROIV) has a robust pipeline with multiple upcoming data readouts, including Phase 3 NIU data and Moseley PNHLD Phase 2B top-line data, suggesting continued growth and innovation. The failure of the betokumab studies in TED was announced, although hyperthyroid patients showed normalization, indicating mixed results in ongoing studies. The Phase 2 study for Mosley is not powered to achieve a p-value on the six-minute walk test, which may limit the immediate impact of the results. There is uncertainty regarding the period two data of the 1,402 study, as the primary endpoint is losing an ACR-20 response, which may not fully capture the drug's efficacy. Roivant Sciences Ltd (NASDAQ:ROIV) faces a competitive landscape in the CLE market, requiring strong data to support its program amidst emerging mechanisms. The company is still analyzing detailed patient-level data and has not yet finalized its path forward with the FDA, indicating potential regulatory hurdles. Q: Can you contextualize the ACR responses seen at 16 weeks, and how might thes...

On Wednesday, Roivant Sciences Ltd. (NASDAQ:ROIV) posted fourth-quarter adjusted earnings per share of $0.28, far surpassing analyst expectations of a $0.29 loss per share. However, quarterly revenue came in at $2.52 million, missing the consensus forecast of $3.76 million. The biotech company’s stock jumped 9.89% in pre-market trading after investors reacted positively to the stronger-than-expected earnings results and upbeat clinical developments. Roivant’s earnings were largely supported by a $770.2 million gain tied to a litigation settlement with Moderna, although the benefit was partially offset by higher research and development spending. Quarterly revenue declined 67% year over year from $7.57 million in the comparable period last year. The company reported income from continuing operations of $355.7 million, a sharp turnaround from the $252.4 million loss recorded a year earlier. “The positive Period 1 data from the IMVT-1402 trial in D2T RA demonstrate exciting potential for a new, differentiated mechanism to treat RA patients who have failed multiple prior therapies,” said Matt Gline, CEO of Roivant. Roivant highlighted encouraging data from its IMVT-1402 study in difficult-to-treat rheumatoid arthritis. The trial delivered Week 16 response rates of 72.7% for ACR20, 54.5% for ACR50, and 35.8% for ACR70. The company also announced that the FDA granted Breakthrough Therapy Designation to brepocitinib for cutaneous sarcoidosis following positive Phase 2 trial results. As of March 31, 2026, Roivant held consolidated cash, cash equivalents, and marketable securities totaling $4.3 billion, which management said is expected to support the business through profitability. Looking ahead, the company plans to launch brepocitinib for dermatomyositis by the end of September 2026. Roivant also expects several clinical data readouts during the second half of calendar year 2026. Roivant stock price

Interested in Roivant Sciences Ltd.? Here are five stocks we like better. IMVT-1402 posted encouraging preliminary results in difficult-to-treat rheumatoid arthritis, with about 73% of evaluable patients achieving ACR20 and more than one-third reaching ACR70. Roivant said the signal looked especially strong in heavily pretreated, JAK- and TNF-experienced patients, though the data are still from an open-label phase. Roivant is preparing for a possible brepocitinib launch in dermatomyositis by the end of September, pending FDA action. The company is also building out commercialization plans while pursuing additional indications such as cutaneous sarcoidosis and lichen planopilaris. The company said it remains well capitalized, ending March 31 with $4.3 billion in cash and equivalents and no debt, plus a planned $950 million upfront payment from its Moderna settlement in July. Roivant also expects several catalysts ahead, including additional IMVT-1402 analysis and mosliciguat data later in the year and beyond. Trump Index: 6 Companies Linked to Trump’s Cabinet Worth Watching Roivant Sciences (NASDAQ:ROIV) executives used the company’s fourth-quarter earnings call to highlight new open-label data for IMVT-1402 in difficult-to-treat rheumatoid arthritis, upcoming pulmonary hypertension data for mosliciguat and continued preparation for a potential brepocitinib launch in dermatomyositis. Chief Executive Matt Gline called the company’s recent period “a pretty wild 12 months,” citing progress across development programs and the previously announced $2.25 billion settlement with Moderna. Gline said Roivant expects to receive the first $950 million upfront portion of that settlement in July. → Vertical Aerospace: Pre-Flight Checks Point to a Breakout The most prominent update centered on preliminary data from the open-label portion of the 1402 study in difficult-to-treat rheumatoid arthritis, or D2T RA. Gline described the results as “surprisingly good,” while cautioning that the data came from an open-label phase of the trial. The study enrolled heavily refractory patients who had failed steroids and DMARDs as well as at least two advanced lines of therapy. Gline said 65% of patients had failed JAK inhibitors, and that “basically every single one” of those patients had also failed a TNF inhibitor. The study also required autoantibody positivity using ACPA criteria....

Q1 total revenue of $179.1M includes estimated license revenue from Genevant related to litigation settlement with Moderna Strong financial position with cash, cash equivalents and marketable securities of $95.2M as of March 31, 2026 FDA granted Fast Track designation to imdusiran, which has the potential to facilitate development and accelerate FDA review WARMINSTER, Pa., May 13, 2026 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq: ABUS) (“Arbutus” or the “Company”), a clinical-stage biopharmaceutical company focused on infectious disease, today reported first quarter 2026 financial results and provided a corporate update. LNP Litigation On March 3, 2026, Arbutus, along with its exclusive licensee, Genevant Sciences (“Genevant”), entered into a settlement agreement to resolve all global patent infringement litigation and patent revocation proceedings involving Moderna. As part of the settlement, Moderna will pay Arbutus and Genevant $950 million upfront in July 2026 (the “Noncontingent Settlement Payment”) and an additional $1.3 billion contingent upon an appellate ruling that 28 U.S.C. §1498 does not bar Arbutus’ and Genevant’s claims against Moderna for patent infringement, except as to doses characterized by the district court as having gone to U.S. government employees. Under the Company’s license with Genevant, the Company expects to receive in July 2026 an estimated $178.7 million of the Noncontingent Settlement Payment, which includes reimbursement of the Company’s litigation costs. In addition, the Company owns approximately 16% of the outstanding common equity of Genevant. For more information about the terms and conditions of the settlement with Moderna, including the contingent payment, please refer to Arbutus’ Quarterly Report on Form 10-Q to be filed with the SEC on May 13, 2026 and Annual Report on Form 10-K filed with the SEC on March 23, 2026. Corporate Updates In April 2026, the U.S. Food and Drug Administration (“FDA”) granted Fast Track designation for imdusiran for the treatment of chronic hepatitis B. The FDA’s Fast Track program is designed to facilitate the development and expedite the review of investigational therapies to treat serious conditions with unmet medical need. A drug granted Fast Track designation may be eligible for several benefits, including earlier and more frequent meetings and communications with the FDA...